CJC-1295 vs HCG
Side-by-Side Comparison
| Attribute | Cjc 1295 | Hcg |
|---|---|---|
| Category | Growth Hormone Secretagogue | Hormonal / Reproductive |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | HCG binds to the LH/CG receptor (LHCGR) on Leydig cells and theca cells with high affinity. In males, this stimulates intratesticular testosterone production, spermatogenesis, and maintains... |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved for anovulation/infertility, hypogonadotropic hypogonadism, prepubertal cryptorchidism. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Common: injection site reactions, headache, fatigue, mood changes; Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 250-500 IU per injection (750-1500 IU/week) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | 3 times per week |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~36,700 g/mol (glycoprotein) |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~24-36 hours |
Overview
CJC-1295 and HCG are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
HCG — Mechanism & Evidence
Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone (MW ~36,700 g/mol) composed of an alpha subunit (shared with LH, FSH, TSH) and a unique beta subunit. Naturally produced by placental trophoblasts during pregnancy, pharmaceutical HCG binds LH/CG receptors in the gonads, stimulating testosterone production in Leydig cells and progesterone in the corpus luteum. It is FDA-approved for multiple reproductive indications and is widely used off-label to maintain testicular function during testosterone replacement therapy (TRT).
Key claims: Maintains testicular function during TRT; Preserves fertility during testosterone use; Triggers ovulation in fertility treatment.
Shared Research Applications
These peptides target different research areas. CJC-1295 focuses on Anti-Aging, Body Composition, while HCG targets Reproductive Health, Hormonal.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
HCG: Common: injection site reactions, headache, fatigue, mood changes Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort Females: ovarian hyperstimulation syndrome (OHSS) — potentially serious
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.